Evidence map›Paper›PMID 19318562›Full record

ArticleCancer research2009

Genome-wide impact of androgen receptor trapped clone-27 loss on androgen-regulated transcription in prostate cancer cells.

Jerome C Nwachukwu, Paolo Mita, Rachel Ruoff, Susan Ha, Qianben Wang, S Joseph Huang, Samir S Taneja, Myles Brown, William L Gerald, Michael J Garabedian and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Cancer research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
0.7field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Androgen receptor coactivators that inhibit prostate cancer growth.American journal of clinical and experimental urology · 2014
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Jerome C NwachukwuDepartment of Pharmacology, New York University School of Medicine, New York, New York 10016, USA.
Paolo Mita
Rachel Ruoff
Susan Ha
Qianben Wang
S Joseph Huang
Samir S Taneja
Myles Brown
William L Gerald
Michael J Garabedian
Susan K Logan
New York University · USHarvard University · USCzech Academy of Sciences, Institute of Microbiology · CZMemorial Sloan Kettering Cancer Center · USYale University · US

Funding

Transcription repression in prostate cancerR01CA112226 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI LOGAN, SUSAN K. · 2008 to 2019
$4.2M
REGULATION OF ANDROGEN RECEPTOR ACTIVITY IN THE PROSTATER01DK058024 · NIDDK · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI GARABEDIAN, MICHAEL J · 2000 to 2003
$1.1M
Genome-Wide Analysis of Transcription Factor Function in Prostate CancerK99CA126160 · NCI · OHIO STATE UNIVERSITY · PI WANG, QIANBEN · 2007 to 2008
$180k
Mechanism of ART-27 Function in Prostate CancerF31CA113285 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI NWACHKWU, JEROME C · 2004 to 2008
$166k
NCI NIH HHS F31 CA113285NCI NIH HHS F31CA113285NCI NIH HHS K99 CA126160NCI NIH HHS K99CA126160NCI NIH HHS R01 CA112226NCI NIH HHS R01CA112226NIDDK NIH HHS R01 DK058024
6 · The paper itself

Abstract

The androgen receptor (AR) directs diverse biological processes through interaction with coregulators such as AR trapped clone-27 (ART-27). Our results show that ART-27 is recruited to AR-binding sites by chromatin immunoprecipitation analysis. In addition, the effect of ART-27 on genome-wide transcription was examined. The studies indicate that loss of ART-27 enhances expression of many androgen-regulated genes, suggesting that ART-27 inhibits gene expression. Surprisingly, classes of genes that are up-regulated upon ART-27 depletion include regulators of DNA damage checkpoint and cell cycle progression, suggesting that ART-27 functions to keep expression levels of these genes low. Consistent with this idea, stable reduction of ART-27 by short-hairpin RNA enhances LNCaP cell proliferation compared with control cells. The effect of ART-27 loss was also examined in response to the antiandrogen bicalutamide. Unexpectedly, cells treated with ART-27 siRNA no longer exhibited gene repression in response to bicalutamide. To examine ART-27 loss in prostate cancer progression, immunohistochemistry was conducted on a tissue array containing samples from primary tumors of individuals who were clinically followed and later shown to have either recurrent or nonrecurrent disease. Comparison of ART-27 and AR staining indicated that nuclear ART-27 expression was lost in the majority of AR-positive recurrent prostate cancers. Our studies show that reduction of ART-27 protein levels in prostate cancer may facilitate antiandrogen-resistant disease.

Indexed as

Androgen AntagonistsAndrogensAnilidesCell Cycle ProteinsCell Growth ProcessesCell Line, TumorGene Expression Regulation, NeoplasticHumansMaleMolecular ChaperonesNeoplasm ProteinsNeoplasm Recurrence, LocalNeoplasms, Hormone-DependentNitrilesProstatic NeoplasmsReceptors, AndrogenAndrogen AntagonistsAndrogensAnilidesbicalutamideCell Cycle ProteinsMolecular ChaperonesNeoplasm ProteinsNitrilesReceptors, AndrogenRNA, MessengerTosyl CompoundsUXT protein, human

Identifiers

PMID19318562
PMCPMC2702238
OpenAlexW2104406476

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.